Trial reportJAMA psychiatry2013
Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.
Trial report in JAMA psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00507728 (Pharmacogenetics, Emotional Reactivity and Smoking), which is not on this map. Cited by 85 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetics, Emotional Reactivity and Smoking
Who cites it
85 citing papers in PubMed, 11 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024.Journal of Korean medical science · 2025Guideline
- The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis.Frontiers in public health · 2024Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Drug and alcohol dependence · 2021Pooled it
- Smoking cessation for improving mental health.The Cochrane database of systematic reviews · 2021Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020Pooled it
- Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis.Lung cancer (Amsterdam, Netherlands) · 2019Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2016Pooled it
- Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2014Pooled it
- Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial.Addiction (Abingdon, England) · 2026Trial
- Characterization of Cognitive-Behavioral Counseling Duration Thresholds for Effective Tobacco Treatment.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Trial
- Standardized research electronic cigarette acceptability among adult men and women who smoke combustible cigarettes.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Trial
- Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo-controlled trial.Addiction (Abingdon, England) · 2023Trial
- Trial
- Trial
- The effect of varenicline on mood and cognition in smokers with HIV.Psychopharmacology · 2020Trial
- Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2019Trial
- Effects of Varenicline, Depressive Symptoms, and Region of Enrollment on Smoking Cessation in Depressed Smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019Trial
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
importanceGiven the actions of varenicline tartrate and bupropion hydrochloride sustained-release (SR) on neurobiological targets related to affect and reward, it is thought that the modulation of nicotine withdrawal symptoms may contribute to their effectiveness.
objectiveTo assess the relative efficacy of varenicline and bupropion SR plus intensive counseling on smoking cessation and emotional functioning. DESIGN AND
settingPlacebo-controlled randomized clinical trial at a university medical center.
participantsIn total, 294 community volunteers who wanted to quit smoking.
interventionsTwelve weeks of varenicline, bupropion SR, or placebo plus intensive smoking cessation counseling (10 sessions, for a total of approximately 240 minutes of counseling).
main outcome measuresProlonged abstinence from smoking and weekly measures of depression, negative affect, and other symptoms of nicotine withdrawal.
resultsSignificant differences were found in abstinence at the end of treatment and through the 3-month postquit follow-up visit, favoring both active medications compared with placebo. At the 6-month postquit follow-up visit, only the varenicline vs placebo comparison remained significant. Varenicline use was also associated with a generalized suppression of depression and reduced smoking reward compared with the other treatments, while both active medications improved concentration, reduced craving, and decreased negative affect and sadness compared with placebo, while having little effect (increase or decrease) on anxiety and anger. No differences were noted in self-reported rates of neuropsychiatric adverse events. CONCLUSIONS AND RELEVANCE: In a community sample, varenicline exerts a robust and favorable effect on smoking cessation relative to placebo and may have a favorable (suppressive) effect on symptoms of depression and other affective measures, with no clear unfavorable effect on neuropsychiatric adverse events.
trial registrationclinicaltrials.gov Identifier: NCT00507728.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.